心脏膜疾病的评估和治疗的未来
Partho P Sengupta1, Jolanda Kluin2, Seung-Pyo Lee3
1Division of Cardiovascular Diseases and Hypertension, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Cardiovascular Services, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
Lancet (London, England)
|March 30, 2024
概括
心脏膜疾病 (VHD) 管理的创新包括人工智能,数字双胞胎和生物工程. 这些进展提高了诊断,风险分层和个性化治疗, 为VHD患者提供了新的希望.
科学领域:
- 心血管医学和生物医学工程
- 计算生物学和药理学
背景情况:
- 在老年人群中,心脏膜疾病 (VHD) 的患病率正在增加,这给诊断和管理带来了挑战.
- 传统的治疗方法面临局限性,特别是在高风险患者群体中.
- 越来越需要创新策略来解决VHD的复杂性.
研究的目的:
- 审查最近在膜心脏病 (VHD) 诊断和治疗方面的进展.
- 突出计算,药物和生物工程创新对VHD护理的影响.
- 探索人工智能 (AI) 和数字技术在个性化VHD治疗中的潜力.
主要方法:
- 对VHD的成像,透管技术和计算方法的当前文献的审查.
- 探索人工智能应用,包括数字双胞胎,用于风险分层和预测.
- 检查VHD的新药学策略和多种方法.
- 讨论生物工程在开发再生心脏膜组织方面的努力.
主要成果:
- 人工智能和数字方法正在改善VHD查,诊断和治疗计划.
- 图像和临床数据的整合提高了VHD的严重程度分类.
- 人工智能驱动的数字双胞胎有助于个性化治疗目标和风险评估.
- 新的药理目标和多种疗法正在确定阻止VHD进展的途径.
- 生物工程正在推进活体心脏管的开发.
结论:
- 计算,药物和生物工程创新正在改变VHD的诊断和管理.
- 早期检测,个性化治疗和先进的干预措施对于优化VHD患者的结果至关重要.
- 这些突破为以患者为中心的研究和改善VHD护理提供了重要机会.
更多相关视频
相关概念视频
01:16Heart Valves
4.6K
The human heart is a complex organ with an intricate system of valves that regulate blood flow. There are two main types of valves: atrioventricular (AV) valves and semilunar valves.
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
4.6K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370